Abstract
Schizophrenia is increasingly recognised as a progressive disorder because the central nervous system (CNS) structure, symptom profile and drug requirements vary with the duration of illness. Changes in gene expression and subsequent levels of CNS protein are likely to underlie the progressive changes in CNS function in schizophrenia. This chapter will review evidence that supports the notion that differential changes in gene expression with duration of illness does occur in the CNS of subjects with schizophrenia. Moreover, the temporal nature of these changes suggests that they may contribute to changes in drug treatment that occurs in the middle years of the disorder. It will be argued that some of the changes in gene expression in the CNS of subjects with schizophrenia may be associated with a differential aging/maturation processes and, that there are fewer differences in gene expression in subjects with schizophrenia of long duration compared to age-sex matched controls than are apparent between subjects with schizophrenia of short duration and their age-sex matched controls. Schizophrenia is a complex disorder and a further understanding of how temporal changes in gene expression contribute to the pathophysiology of the illness is likely to underpin a better understanding of the changes in CNS structure, symptom profile and treatment regimes that have been associated with the disorder.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- BA:
-
Brodmann’s area
- CDC42BPB:
-
Cell division cycle 42 binding protein kinase β (DMPK-like)
- CNS:
-
Central nervous system
- DLPFC:
-
Dorsolateral prefrontal cortex
- DSC2:
-
Desmocollin 2
- LRP:
-
Low density lipoprotein receptor-related protein
- MBNL1:
-
Muscleblind protein 1
- NCAM1:
-
Neural cell adhesion molecule 1
- PCDH17:
-
Protocadherin 17
- PTPRE:
-
Protein tyrosine phosphatase receptor type E
- RFDD:
-
Restrictive fragment differential display
- RGS4:
-
Regulator of G protein signaling 4
References
DeLisi LE (1997) Is schizophrenia a lifetime disorder of brain plasticity, growth and aging? Schizophr Res 23:119–129
Puri BK (2010) Progressive structural brain changes in schizophrenia. Expert Rev Neurother 10:33–42
Tsuang MT, Stone WS, Faraone SV (2001) Genes, environment and schizophrenia. Br J Psychiatry Suppl 40:s18–s24
Dean B, Keriakous D, Scarr E et al (2007) Gene expression profiling in Brodmann’s area 46 from subjects with schizophrenia. Aust NZ J Psychiatry 41:308–320
Mirnics K, Levitt P, Lewis DA (2006) Critical appraisal of DNA microarrays in psychiatric genomics. Biol Psychiatry 60:163–176
Weinberger DR (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44:660–669
Gur RE, Petty RG, Turetsky BI et al (1996) Schizophrenia throughout life: sex differences in severity and profile of symptoms. Schizophr Res 21:1–12
Moberg PJ, Doty RL, Turetsky BI et al (1997) Olfactory identification deficits in schizophrenia: correlation with duration of illness. Am J Psychiatry 154:1016–1018
Kosmidis MH, Bozikas VP, Vlahou CH et al (2005) Verbal fluency in institutionalized patients with schizophrenia: age-related performance decline. Psychiatry Res 134:233–240
Mitelman SA, Canfield EL, Newmark RE et al (2009) Longitudinal assessment of gray and white matter in chronic schizophrenia: a combined diffusion-tensor and structural magnetic resonance imaging study. Open Neuroimag J 3:31–47
Premkumar P, Fannon D, Kuipers E et al (2008) Association between a longer duration of illness, age and lower frontal lobe grey matter volume in schizophrenia. Behav Brain Res 193:132–139
Lehrmann E, Hyde TM, Vawter MP et al (2003) The use of microarrays to characterize neuropsychiatric disorders: postmortem studies of substance abuse and schizophrenia. Curr Mol Med 3:437–446
Narayan S, Tang B, Head SR et al (2008) Molecular profiles of schizophrenia in the CNS at different stages of illness. Brain Res 1239:235–248
Convit A, Wolf OT, de Leon MJ et al (2001) Volumetric analysis of the pre-frontal regions: findings in aging and schizophrenia. Psychiatry Res 107:61–73
Zhu YX, Benn S, Li ZH et al (2004) The SH3-SAM adaptor HACS1 is up-regulated in B cell activation signaling cascades. J Exp Med 200:737–747
Wang D, Stewart AK, Zhuang L et al (2010) Enhanced adaptive immunity in mice lacking the immunoinhibitory adaptor Hacs1. FASEB J 24:947–956
Chen XQ, Tan I, Leung T et al (1999) The myotonic dystrophy kinase-related Cdc42-binding kinase is involved in the regulation of neurite outgrowth in PC12 cells. J Biol Chem 274:19901–19905
Greenwood MD, Marsden MD, Cowley CM et al (1997) Exon-intron organization of the human type 2 desmocollin gene (DSC2): desmocollin gene structure is closer to “classical” cadherins than to desmogleins. Genomics 44:330–335
Okubo K, Aida K (2003) Gonadotropin-releasing hormone gene products downregulate the expression of their neighboring genes that encode protein tyrosine phosphatases alpha and ɛ. Biochem Biophys Res Commun 312:531–536
Coulibaly I, Page GP (2008) Bioinformatic tools for inferring functional information from plant microarray data II: analysis beyond single gene. Int J Plant Genomics 2008:893941
Uchida H, Suzuki T, Mamo DC et al (2008) Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: a survey of 1,418 patients in Japan. Am J Geriatr Psychiatry 16:584–593
Kurtz MM (2005) Neurocognitive impairment across the lifespan in schizophrenia: an update. Schizophr Res 74:15–26
Harrison PJ (2007) Schizophrenia susceptibility genes and their neurodevelopmental implications: focus on neuregulin 1. Novartis Found Symp 288:246–255
Tang B, Chang WL, Lanigan CM et al (2009) Normal human aging and early-stage schizophrenia share common molecular profiles. Aging Cell 8:339–342
Kirkpatrick B, Messias E, Harvey PD et al (2008) Is schizophrenia a syndrome of accelerated aging? Schizophr Bull 34:1024–1032
Dean B, Keriakous D, Scarr E et al (2005) Understanding the pathology of schizophrenia: the impact of high-throughput screening of the genome and proteome in postmortem CNS. Curr Opin Psych Rev 1:1–9
Chen X, Sun C, Chen Q et al (2009) Apoptotic engulfment pathway and schizophrenia. PLoS One 4:e6875–e6879
Catts VS, Catts SV, McGrath JJ et al (2006) Apoptosis and schizophrenia: a pilot study based on dermal fibroblast cell lines. Schizophr Res 84:20–28
Goldman-Rakic PS, Selemon LD (1997) Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull 23:437–458
Beckmann H, Lauer M (1997) The human striatum in schizophrenia. II. Increased number of striatal neurons in schizophrenics. Psychiatry Res 68:99–109
Nishioka N, Arnold SE (2004) Evidence for oxidative DNA damage in the hippocampus of elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry 12:167–175
Young J, McKinney SB, Ross BM et al (2007) Biomarkers of oxidative stress in schizophrenic and control subjects. Prostaglandins Leukot Essent Fatty Acids 76:73–85
Psimadas D, Messini-Nikolaki N, Zafiropoulou M et al (2004) DNA damage and repair efficiency in lymphocytes from schizophrenic patients. Cancer Lett 204:33–40
Mirnics K, Middleton FA, Stanwood GD et al (2001) Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry 6:293–301
Chowdari KV, Mirnics K, Semwal P et al (2002) Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum Mol Genet 11:1373–1380
Morris DW, Rodgers A, McGhee KA et al (2004) Confirming RGS4 as a susceptibility gene for schizophrenia. Am J Med Genet B Neuropsychiatr Genet 125B:50–53
Williams NM, Preece A, Spurlock G et al (2004) Support for RGS4 as a susceptibility gene for schizophrenia. Biol Psychiatry 55:192–195
Bowden NA, Scott RJ, Tooney PA (2007) Altered expression of regulator of G-protein signalling 4 (RGS4) mRNA in the superior temporal gyrus in schizophrenia. Schizophr Res 89:165–168
Erdely HA, Tamminga CA, Roberts RC et al (2006) Regional alterations in RGS4 protein in schizophrenia. Synapse 59:472–479
Gibbons AS, Scarr E, McOmish CE et al (2008) Regulator of G-protein signalling 4 expression is not altered in the prefrontal cortex in schizophrenia. Aust NZ J Psychiatry 42:740–745
Lipska BK, Mitkus S, Caruso M et al (2006) RGS4 mRNA expression in postmortem human cortex is associated with COMT Val158Met genotype and COMT enzyme activity. Hum Mol Genet 15:2804–2812
Vilella E, Costas J, Sanjuan J et al (2008) Association of schizophrenia with DTNBP1 but not with DAO, DAOA, NRG1 and RGS4 nor their genetic interaction. J Psychiatr Res 42:278–288
Ishiguro H, Horiuchi Y, Koga M et al (2007) RGS4 is not a susceptibility gene for schizophrenia in Japanese: association study in a large case-control population. Schizophr Res 89:161–164
Li D, He L (2006) Association study of the G-protein signaling 4 (RGS4) and proline dehydrogenase (PRODH) genes with schizophrenia: a meta-analysis. Eur J Hum Genet 14:1130–1135
Torkamani A, Dean B, Schork NJ et al (2010) Coexpression network analysis of neural tissue reveals perturbations in developmental processes in schizophrenia. Genome Res 20:403–412
Pennington K, Dicker P, Dunn MJ et al (2008) Proteomic analysis reveals protein changes within layer 2 of the insular cortex in schizophrenia. Proteomics 8:5097–5107
Miyoshi K, Honda A, Baba K et al (2003) Disrupted-in-schizophrenia 1, a candidate gene for schizophrenia, participates in neurite outgrowth. Mol Psychiatry 8:685–694
Carlsson A (1977) Does dopamine play a role in schizophrenia? Psychol Med 7:583–597
Bjorklund A, Dunnett SB (2007) Dopamine neuron systems in the brain: an update. Trends Neurosci 30:194–202
Moller HJ, Bottlender R, Wegner U et al (2000) Long-term course of schizophrenic, affective and schizoaffective psychosis: focus on negative symptoms and their impact on global indicators of outcome. Acta Psychiatr Scand 102(Suppl 407):54–57
Colantuoni C, Hyde TM, Mitkus S et al (2008) Age-related changes in the expression of schizophrenia susceptibility genes in the human prefrontal cortex. Brain Struct Funct 213:255–271
Siegmund KD, Connor CM, Campan M et al (2007) DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. PLoS One doi:10.1371/journal.pone.0012002
Handel AE, Ebers GC, Ramagopalan SV (2010) Epigenetics: molecular mechanisms and implications for disease. Trends Mol Med 16:7–16
Gibbons AS, Thomas EA, Dean B (2009) Regional and duration of illness differences in the alteration of NCAM-180 mRNA expression within the cortex of subjects with schizophrenia. Schizophr Res 112:65–71
Ni Dhuill CM, Fox GB, Pittock SJ et al (1999) Polysialylated neural cell adhesion molecule expression in the dentate gyrus of the human hippocampal formation from infancy to old age. J Neurosci Res 55:99–106
Rutishauser U (2008) Polysialic acid in the plasticity of the developing and adult vertebrate nervous system. Nat Rev Neurosci 9:26–35
Gray LJ, Dean B, Kronsbein HC et al (2010) Region and diagnosis-specific changes in synaptic proteins in schizophrenia and bipolar I disorder. Psychiatry Res 178(2):374–380
Sytnyk V, Leshchyns’ka I, Nikonenko AG et al (2006) NCAM promotes assembly and activity-dependent remodeling of the postsynaptic signaling complex. J Cell Biol 174:1071–1085
Kowal RC, Herz J, Weisgraber KH et al (1990) Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem 265:10771–10779
Schneider WJ, Nimpf J (2003) LDL receptor relatives at the crossroad of endocytosis and signaling. Cell Mol Life Sci 60:892–903
Dean B, Laws SM, Hone E et al (2003) Increased levels of apolipoprotein E in the frontal cortex of subjects with schizophrenia. Biol Psychiatry 54:616–622
Digney A, Keriakous D, Scarr E et al (2005) Differential changes in apolipoprotein E in schizophrenia and bipolar I disorder. Biol Psychiatry 57:711–715
Impagnatiello F, Guidotti AR, Pesold C et al (1998) A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc Natl Acad Sci USA 95:15718–15723
Gibbons AS, Thomas EA, Scarr E et al (2010) Low-density lipoprotein receptor-related protein and apolipoprotein E expression is altered in schizophrenia. Front Psychiatry doi:10.3389/fpsyt.2010.00019
Sugiyama T, Kumagai H, Morikawa Y et al (2000) A novel low-density lipoprotein receptor-related protein mediating cellular uptake of apolipoprotein E-enriched beta-VLDL in vitro. Biochemistry 39:15817–15825
Siest G, Pillot T, Regis-Bailly A et al (1995) Apolipoprotein E: an important gene and protein to follow in laboratory medicine. Clin Chem 41:1068–1086
Dumanis SB, Tesoriero JA, Babus LW et al (2009) ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo. J Neurosci 29:15317–15322
Brans RG, van Haren NE, van Baal GC et al (2008) Longitudinal MRI study in schizophrenia patients and their healthy siblings. Br J Psychiatry 193:422–423
Farrow TF, Whitford TJ, Williams LM et al (2005) Diagnosis-related regional gray matter loss over two years in first episode schizophrenia and bipolar disorder. Biol Psychiatry 58:713–723
Whitford TJ, Grieve SM, Farrow TF et al (2007) Volumetric white matter abnormalities in first-episode schizophrenia: a longitudinal, tensor-based morphometry study. Am J Psychiatry 164:1082–1089
DeLisi LE, Sakuma M, Maurizio AM et al (2004) Cerebral ventricular change over the first 10 years after the onset of schizophrenia. Psychiatry Res 130:57–70
Ho BC, Andreasen NC, Nopoulos P et al (2003) Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry 60:585–594
Mathalon DH, Sullivan EV, Lim KO et al (2001) Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Arch Gen Psychiatry 58:148–157
Maier M, Ron MA (1996) Hippocampal age-related changes in schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr Res 22:5–17
Pantelis C, Velakoulis D, McGorry PD et al (2003) Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 361:281–288
Wang L, Mamah D, Harms MP et al (2008) Progressive deformation of deep brain nuclei and hippocampal-amygdala formation in schizophrenia. Biol Psychiatry 64:1060–1068
Chakos MH, Schobel SA, Gu H et al (2005) Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia. Br J Psychiatry 186:26–31
Sporn AL, Greenstein DK, Gogtay N et al (2003) Progressive brain volume loss during adolescence in childhood-onset schizophrenia. Am J Psychiatry 160:2181–2189
Giedd JN, Jeffries NO, Blumenthal J et al (1999) Childhood-onset schizophrenia: progressive brain changes during adolescence. Biol Psychiatry 46:892–898
Salisbury DF, Kuroki N, Kasai K et al (2007) Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. Arch Gen Psychiatry 64:521–529
Meagher DJ, Quinn JF, Bourke S et al (2004) Longitudinal assessment of psychopathological domains over late-stage schizophrenia in relation to duration of initially untreated psychosis: 3-year prospective study in a long-term inpatient population. Psychiatry Res 126:217–227
Fornito A, Yucel M, Dean B et al (2009) Anatomical abnormalities of the anterior cingulate cortex in schizophrenia: bridging the gap between neuroimaging and neuropathology. Schizophr Bull 35:973–993
Jaaro-Peled H, Ayhan Y, Pletnikov MV et al (2010) Review of pathological hallmarks of schizophrenia: comparison of genetic models with patients and nongenetic models. Schizophr Bull 36:301–313
Perez-Costas E, Melendez-Ferro M, Roberts RC (2010) Basal ganglia pathology in schizophrenia: dopamine connections and anomalies. J Neurochem 113:287–302
Wang Y, Stricker HM, Gou D et al (2007) MicroRNA: past and present. Front Biosci 12:2316–2329
Dean B, Pavey G, Smith I (2008) Using differential solubilization and 2-D gel electrophoresis to visualize increased numbers of proteins in the human cortex and caudate nucleus and putamen. Proteomics – Clin Appl 2:1281–1289
Tamminga CA (2008) Accelerating new knowledge in schizophrenia. Am J Psychiatry 165:949–951
Scarr E, Cowie TF, Kanellakis S et al (2009) Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol Psychiatry 14:1017–1023
Maheswaran S, Barjat H, Rueckert D et al (2009) Longitudinal regional brain volume changes quantified in normal aging and Alzheimer’s APP x PS1 mice using MRI. Brain Res 1270:19–32
Scheff SW, Price DA, Sparks DL (2001) Quantitative assessment of possible age-related change in synaptic numbers in the human frontal cortex. Neurobiol Aging 22:355–365
Acknowledgements
BD is an NH&MRC Senior Research Fellow (# 400016) and ES is the ARHRF Royce Abbey Post-Doctoral Fellow. Much of the data reviewed in was generated from research funded by MH069696-01.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Dean, B., Gibbons, A., Scarr, E., Thomas, E.A. (2011). Changes in Gene Expression in Subjects with Schizophrenia Associated with Disease Progression. In: Ritsner, M. (eds) Handbook of Schizophrenia Spectrum Disorders, Volume I. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-0837-2_10
Download citation
DOI: https://doi.org/10.1007/978-94-007-0837-2_10
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-0836-5
Online ISBN: 978-94-007-0837-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)